Pilot Testing Suicide Risk Prediction Algorithms in Primary Care
Launched by KAISER PERMANENTE · Jul 15, 2025
Trial Information
Current as of November 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is testing a new way to help doctors in primary care (your regular doctor’s office) identify adults who might be at risk for suicide. The researchers want to see if using a special computer program, called a suicide risk prediction algorithm, can help spot people who could benefit from extra support and safety planning to keep them safe. They will look at how this tool affects the number of patients who report having suicidal thoughts, how many are identified as needing safety plans, and how many actually take part in those safety plans.
Adults visiting primary care clinics at Kaiser Permanente Washington between February 2025 and March 2026 may be included, as long as they are 18 years or older. If you join, your doctor’s office will use the algorithm to help decide if you need extra mental health monitoring during your visit. The study is not yet recruiting participants, but it’s designed to learn if this approach can better support people’s mental health and prevent suicide.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: Any type of adult primary care visit/encounter at Kaiser Permanente Washington (KPWA) between 2/1/2025-8/31/2025 (pre period) or 9/1/2025-3/31/2026 (post-period or implementation period).
- • Exclusion Criteria: Primary care visit/encounter among people under 18 years old.
About Kaiser Permanente
Kaiser Permanente is a leading integrated health care organization that combines a health plan with a network of hospitals and physicians to provide comprehensive medical services. With a strong commitment to advancing medical research and improving patient care, Kaiser Permanente sponsors clinical trials across various therapeutic areas. The organization emphasizes innovative approaches to health care, leveraging its extensive data and resources to support evidence-based treatments and enhance patient outcomes. Through its rigorous research initiatives, Kaiser Permanente aims to contribute to the advancement of medical knowledge and the development of new therapies that benefit diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported